MedTrace Logo

Haplo-SCT vs ASCT With or Without Decitabine in AML CR1

NCT02059720 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2020-02-05

No results posted yet for this study

Summary

A multicentre, prospective, open-label clinical study, including a randomized controlled study in low or intermediate-risk group patients, and a cohort study of maintenance treatment with decitabine after ASCT.

Conditions

Interventions

PROCEDURE

HSCT

Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.

Sponsors & Collaborators

  • European Society for Blood and Marrow Transplantation

    collaborator NETWORK

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Depei Wu, M.D., Ph.D. · The First Affiliated Hospital of Soochow University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02059720 on ClinicalTrials.gov